2598. Activity of Aztreonam-Avibactam and Other β-Lactamase Inhibitor Combinations against Gram-negative Bacteria Isolated from Patients Hospitalized with Pneumonia in US Medical Centers (2020–2022)

BACKGROUND: Resistance to recently approved β-lactamase inhibitor combinations, such as ceftazidime-avibactam (CAZ-AVI) and meropenem-vaborbactam (MEM-VAB), appears to be increasing among carbapenem-resistant Enterobacterales (CRE) in some US hospitals. We evaluated the frequency and antimicrobial s...

Descripción completa

Detalles Bibliográficos
Autores principales: Sader, Helio S, Mendes, Rodrigo E, Duncan, Leonard R, Doyle, Timothy, Castanheira, Mariana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678652/
http://dx.doi.org/10.1093/ofid/ofad500.2213

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678652/
http://dx.doi.org/10.1093/ofid/ofad500.2213

Ejemplares similares